216 related articles for article (PubMed ID: 17253547)
1. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers J; Chaudhry V; Cavaletti G; Donehower R
Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
[TBL] [Abstract][Full Text] [Related]
2. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers JW; Chaudhry V; Cavaletti G; Donehower RC
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD005228. PubMed ID: 24687190
[TBL] [Abstract][Full Text] [Related]
3. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers JW; Chaudhry V; Cavaletti G; Donehower RC
Cochrane Database Syst Rev; 2011 Feb; (2):CD005228. PubMed ID: 21328275
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
6. Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Worthington HV; Clarkson JE; Eden OB
Cochrane Database Syst Rev; 2006 Apr; (2):CD000978. PubMed ID: 16625538
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.
Pace A; Giannarelli D; Galiè E; Savarese A; Carpano S; Della Giulia M; Pozzi A; Silvani A; Gaviani P; Scaioli V; Jandolo B; Bove L; Cognetti F
Neurology; 2010 Mar; 74(9):762-6. PubMed ID: 20194916
[TBL] [Abstract][Full Text] [Related]
8. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
9. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Moore DH; Donnelly J; McGuire WP; Almadrones L; Cella DF; Herzog TJ; Waggoner SE;
J Clin Oncol; 2003 Nov; 21(22):4207-13. PubMed ID: 14615449
[TBL] [Abstract][Full Text] [Related]
10. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
Pace A; Bove L; Jandolo B
Neurology; 2005 Aug; 65(3):501-2; author reply 501-2. PubMed ID: 16087937
[No Abstract] [Full Text] [Related]
11. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
Benstead TJ; Chalk CH; Parks NE
Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
[TBL] [Abstract][Full Text] [Related]
12. Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Clarkson JE; Worthington HV; Eden OB
Cochrane Database Syst Rev; 2003; (3):CD000978. PubMed ID: 12917895
[TBL] [Abstract][Full Text] [Related]
13. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006282. PubMed ID: 22161400
[TBL] [Abstract][Full Text] [Related]
14. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
[TBL] [Abstract][Full Text] [Related]
15. Protection of cisplatin-induced neuropathy: recent developments.
Hamers F; Neijt J; Gispen W
Pathol Biol (Paris); 1992 Nov; 39(9):829-30. PubMed ID: 1311436
[No Abstract] [Full Text] [Related]
16. Pharmacological interventions to reduce platinum-induced toxicity.
Tognella S
Cancer Treat Rev; 1990 Sep; 17(2-3):139-42. PubMed ID: 2176930
[No Abstract] [Full Text] [Related]
17. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity.
Bianchi R; Brines M; Lauria G; Savino C; Gilardini A; Nicolini G; Rodriguez-Menendez V; Oggioni N; Canta A; Penza P; Lombardi R; Minoia C; Ronchi A; Cerami A; Ghezzi P; Cavaletti G
Clin Cancer Res; 2006 Apr; 12(8):2607-12. PubMed ID: 16638873
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.
Pace A; Savarese A; Picardo M; Maresca V; Pacetti U; Del Monte G; Biroccio A; Leonetti C; Jandolo B; Cognetti F; Bove L
J Clin Oncol; 2003 Mar; 21(5):927-31. PubMed ID: 12610195
[TBL] [Abstract][Full Text] [Related]
19. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
[TBL] [Abstract][Full Text] [Related]
20. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.
Vogel AP; Folker J; Poole ML
Cochrane Database Syst Rev; 2014 Oct; (10):CD008953. PubMed ID: 25348587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
